Written by: rashmi 11/15/2010 11:18 AM
Following recommendations of an expert committee, the Drugs Controller General of India (DCGI) on Friday ordered the “suspension” of the manufacture and import of anti-obesity drug Sibutramine after the medicine showed serious side effects, including heart attack, among some users. The DCGI also recommended to the Ministry of Health and Family Welfare a total ban on the sale of the drug. The suspension order was issued under Section 26 (A) of Drugs and Cosmetic Act, with immediate effect, with the DCGI also seeking a total prohibition on its manufacture and sale in the open market. Orlistat is the only drug now available in the market for obesity management.
Following recommendations of an expert committee, the Drugs Controller General of India (DCGI) on Friday ordered the “suspension” of the manufacture and import of anti-obesity drug Sibutramine after the medicine showed serious side effects, including heart attack, among some users. The DCGI also recommended to the Ministry of Health and Family Welfare a total ban on the sale of the drug. The suspension order was issued under Section 26 (A) of Drugs and Cosmetic Act, with immediate effect, with the DCGI also seeking a total prohibition on its manufacture and sale in the open market.
Orlistat is the only drug now available in the market for obesity management.
0 comments so far...